By Euro Weekly News Media • 19 March 2021 • 15:31
Osteoarthritis is a disabling, non-curable and progressive disease that is concentrated in the joints, but in advanced stages it affects the general health of the dog and can be the cause of euthanasia due to the loss of quality of life.
A multimodal management of the disease is necessary, which involves a combination of different medical therapies such as non-steroidal anti-inflammatory drugs and analgesics, nutraceuticals, an adequate diet, weight control and exercise management, and sometimes surgery.
One of the great novelties in the treatment of osteoarthritis is bedinvetmab. It is an injection of moncoclonal antibodies that act against the so-called nerve growth factor.
This factor is a key component in osteoarthritis pain and causes the release of pro-inflammatory mediators. This will reduce the need for oral anti-inflammatory medications that some dogs do not tolerate well.
After one injection of bedinvetmab, dogs with osteoarthritis exhibited increased mobility and decreased pain. José Rial, accredited AVEPA in Traumatology and Orthopaedics.
In Costablanca Norte: Anicura Marina Baixa Hospital Veterinario www.veterinariamarinabaixa.com
In Costablanca Sur: Centro Veterinario de Diagnóstico por Imagen de Levante www.resonanciaveterinaria.es
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don't already have one. Review our Privacy Policy for more information about our privacy practices.
Share your story with us by emailing newsdesk@euroweeklynews.com, by calling +34 951 38 61 61 or by messaging our Facebook page www.facebook.com/EuroWeeklyNews
By signing up, you will create a Euro Weekly News account if you don’t already have one. Review our Privacy Policy for more information about our privacy practices.
Download our media pack in either English or Spanish.